DESCRIPTION
ibandronate
CLASSIFICATION
bisphosphonates
MECHANISM OF ACTION
The action of ibandronate on bone tissue is based on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover.
ABSORPTION
Oral ibandronate is 0.63% bioavailable.8 In a study of healthy males, a 10mg oral dose had a Tmax of 1.1±0.6h and a Cmax of 4.1±2.6ng/mL.10 The Tmax is approximately 1 hour, while Cmax varies depending on dose.10
A 2mg intravenous dose of ibandronate has an AUC of 316ng*h/mL, a 4mg intravenous dose of ibandronate has an AUC of 581ng*h/mL, and a 6mg intravenous dose of ibandronate has an AUC of 908ng*h/mL.9
DISTRIBUTION
The apparent terminal volume of distribution of ibandronate is 90-368L in headlthy subjects and 103L in postmenopausal women with osteopenia.
INDICATIONS
For the treatment and prevention of osteoporosis in postmenopausal women.
DRUG INTERACTION
Drug interactions of Boniva include calcium supplements, antacids, and other products that contain aluminum, magnesium, or iron, which may reduce absorption of Boniva. Irritation in the stomach and intestines may increase if aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are combined with Boniva.
TOXICITY
Patients experiencing an overdose may present with hypocalcemia, hypophosphatemia, upset stomach, dyspepsia, esophagitis, and uclers.Oral overdose can be managed by giving patients milk or antacids to bind excess unabsorbed ibandronate. Overdoses can be managed by providing intravenous electrolytes and dialysis is not expected to remove excess drug from serum.
SPECIFICATION
Login To Comment